Trastuzumab adds to adjuvant chemotherapy for resected HER2-positive breast cancer

被引：3
|
作者：
Hudis, CA [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Breast Canc Med Serv, New York, NY 10021 USA
来源：
NATURE CLINICAL PRACTICE ONCOLOGY | 2006年 / 3卷 / 01期
关键词：
breast cancer; chemotherapy; HER2; survival; trastuzumab;
D O I：
10.1038/ncponc0401
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：12 / 13
页数：2
相关论文
共 50 条
  • [21] HER2-positive breast cancer brain metastases: multiple responses to systemic chemotherapy and trastuzumab - a case report
    Church, D. N.
    Bahl, A.
    Jones, A.
    Price, C. G. A.
    JOURNAL OF NEURO-ONCOLOGY, 2006, 79 (03) : 289 - 292
  • [22] HER2-positive Breast Cancer Brain Metastases: Multiple Responses to Systemic Chemotherapy and Trastuzumab—a Case Report
    D. N. Church
    A. Bahl
    A. Jones
    C. G. A. Price
    Journal of Neuro-Oncology, 2006, 79 : 289 - 292
  • [23] Brain metastases in HER2-positive metastatic breast cancer patients who received chemotherapy with or without trastuzumab
    Kaplan, Muhammet Ali
    Ertugrul, Hamza
    Firat, Ugur
    Kucukoner, Mehmet
    Inal, Ali
    Urakci, Zuhat
    Pekkolay, Zafer
    Isikdogan, Abdurrahman
    BREAST CANCER, 2015, 22 (05) : 503 - 509
  • [24] Cost-effectiveness analysis of trastuzumab monotherapy versus adjuvant chemotherapy plus trastuzumab in elderly patients with HER2-positive early breast cancer
    Konishi, Takaaki
    Fujiogi, Michimasa
    Michihata, Nobuaki
    Ohbe, Hiroyuki
    Matsui, Hiroki
    Fushimi, Kiyohide
    Tanabe, Masahiko
    Seto, Yasuyuki
    Yasunaga, Hideo
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (10) : 1115 - 1123
  • [25] Effect of Adjuvant/Neoadjuvant Trastuzumab on Clinical Outcomes in Patients With HER2-Positive Metastatic Breast Cancer
    Murthy, Rashmi K.
    Varma, Ankur
    Mishra, Priyankana
    Hess, Kenneth R.
    Young, Elliana
    Murray, James L.
    Koenig, Kimberly H.
    Moulder, Stacy L.
    Melhem-Bertrandt, Amal
    Giordano, Sharon H.
    Booser, Daniel
    Valero, Vicente
    Hortobagyi, Gabriel N.
    Esteva, Francisco J.
    CANCER, 2014, 120 (13) : 1932 - 1938
  • [26] Clinicopathologic Significance of the Intratumoral Heterogeneity of HER2 Gene Amplification in HER2-Positive Breast Cancer Patients Treated With Adjuvant Trastuzumab
    Lee, Hee Jin
    Kim, Joo Young
    Park, So Yeon
    Park, In Ah
    Song, In Hye
    Yu, Jong Han
    Ahn, Jin-Hee
    Gong, Gyungyub
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2015, 144 (04) : 570 - 578
  • [27] Efficacy of Adjuvant Combination Therapy With Trastuzumab and Chemotherapy in HER2-positive Early Breast Cancer: A Single Institutional Cohort Study from Clinical Practice
    Okamoto, Masahiro
    Tajiri, Wakako
    Ueo, Hiroki
    Masuda, Takanobu
    Ijichi, Hideki
    Koga, Chinami
    Nakamura, Yoshiaki
    Taguchi, Kenichi
    Ohno, Shinji
    Tokunaga, Eriko
    ANTICANCER RESEARCH, 2020, 40 (06) : 3315 - 3323
  • [28] Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer
    Cadoo, Karen A.
    Morris, Patrick G.
    Cowell, Elizabeth P.
    Patil, Sujata
    Hudis, Clifford A.
    McArthur, Heather L.
    CLINICAL BREAST CANCER, 2016, 16 (06) : 487 - 493
  • [29] Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
    Mueller, Volkmar
    Clemens, Michael
    Jassem, Jacek
    Al-Sakaff, Nedal
    Auclair, Petra
    Nuesch, Eveline
    Holloway, Debbie
    Shing, Mona
    Bang, Yung-Jue
    BMC CANCER, 2018, 18
  • [30] Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States
    Garrison, Louis P., Jr.
    Babigumira, Joseph
    Tournier, Clement
    Goertz, Hans-Peter
    Lubinga, Solomon J.
    Perez, Edith A.
    VALUE IN HEALTH, 2019, 22 (04) : 408 - 415
12345